Jennifer Sun is an Ophthalmology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Beetham Eye Institute
1 Joslin Place
Boston, MA 02215
Telephone
617-732-2554Registry record last updated 8 Jul 2007.
Clinical trials
- Anti-VEGF Treatment for Prevention of PDR/DME
Sponsor: Jaeb Center for Health Research
- A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
Sponsor: KalVista Pharmaceuticals, Ltd.
- OCT Screening for Diabetic Macular Edema at Primary Diabetes Care Visits
Sponsor: Joslin Diabetes Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alcon Vision LLCProgram year20241 payment
- Alcon Vision LLCProgram year20231 payment
- Novo Nordisk IncProgram year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
47.3%Prostaglandin Analog26.6%Latanoprost100%Part D≥23 patientsCarbonic Anhydrase Inhibitor10.8%Dorzolamide Hcl50%Dorzolamide-Timolol50%Part D<11 patients+ 1 more class in this area
Cancer & immunology
44%Vascular Endothelial Growth Factor Inhibitor44%Aflibercept100%Part B, office-administered≥22 patientsCardiovascular
8.7%Beta blocker8.7%Timolol Maleate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2014–2018 per NIH RePORTER. The latest:
- Predicting Outcomes & Anti-VEGF Response in Diabetic Eyes by Adaptive Optics SLO
Joslin Diabetes Center
FY2018$352,614R01EY024702 - Predicting Outcomes & Anti-VEGF Response in Diabetic Eyes by Adaptive Optics SLO
Joslin Diabetes Center
FY2017$352,614R01EY024702 - Predicting Outcomes & Anti-VEGF Response in Diabetic Eyes by Adaptive Optics SLO
Joslin Diabetes Center
FY2016$317,352R01EY024702
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”